

Receipt date: 08/17/2006

Please type a plus sign (+) inside this box →

10/589851  
IAP14 Rec'd PCT/PTO 17 AUG 2006

10589851 - GAU: 1644

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	not yet assigned
		Filing Date	concurrently
		First Named Inventor	John TROWSDALE
		Group Art Unit	not yet assigned
Examiner Name	not yet assigned	Attorney Docket Number	MEWB-013/00US
Sheet	1 of 2		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
/MS/	1	RADOSAVLJEVIC M ET AL: "A cluster of ten novel MHC class 1 related genes on human chromosome 6q24.2-q.25.3" GENOMICS, ACADEMIC PRESS, SAN DIEGO, US. vol. 79, no. 1, January 2002 (2002-01), pages 114-123, XP002314793 ISSN: 0888-7543 page 117- page 121: table 1 & DATABASE EMBL 'Online! 12 February 2002 (2002-02-12), "Homo sapiens retinoic acid early transcript 1 (RAET1L) mRNA, complete cds." XP002341481 retrieved from EB1 accession no. EM_PRO:AY039682 Database accession no. AY039682.				
/MS/	2	WO 03/054152 A (HYSEQ, INC; TANG, Y. , TOM: ASUNDI, VINOD; GOODRICH, RYLE, W; REN, FEIY) 3 July 2003 (2003-07-03) sequences 273, 1184 & DATABASE Geneseq 'Online! 29 January 2004 (2004-01-29), "Novel protein (useful for identifying genetic disorders) #273." XP002341482 retrieved from EBI accession no. GSN: ADE08118 Database accession no. ADE08118 & DATABASE Geneseq 'Online! 29 January 2004 (2004-01-29), "Novel coding sequence (useful for identifying genetic disorders) #273." XP002341483 retrieved from EBI accession no. GSN: ADE07207 Database accession no. ADE07207				
/MS/	3	DATABASE EMBL 'Online! 7 March 2000 (2000-03-07) "hd39b04.x1 Soares NFL_T GBC SI Homo sapiens cDNA clone IMAGE:2911855 3' similar to SW:ZA2G_MOUSEF064726 ZINC-ALPHA-2 GLYCOPROTEIN PRECURSOR : mRNA sequence." XP002341484 retrieved from EBI accession no. EM_PRO: AW510737 Database accession no. AW510737 the whole document				
Examiner Signature	/Michael Szperka/			Date Considered	07/12/2010	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number (optional). <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Receipt date: 08/17/2006

10/589851  
 IAP14 Rec'd PCT/PTO 17 AUG 2006  
 PTO/SB/08A (07-05)  
 Approved for use through 07/31/2006. OMB 0651-0031  
 89851 - GAU: 1644

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	not yet assigned
		Filing Date	concurrently
		First Named Inventor	John TROWSDALE
		Group Art Unit	not yet assigned
Examiner Name	not yet assigned	Attorney Docket Number	MEWB-013/00US
Sheet	2 of 2		

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/MS/	4	COSMAN D ET AL: "ULBPs, Novel MHC class 1-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor" IMMUNITY, CELL PRESS, US, vol. 14, no. 2, February 2001 (2001-02), pages 123-133, XP002314794 ISSN: 1074-7613	
/MS/	5	BACON LOUISE ET AL: "Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D" JOURNAL OF IMMUNOLOGY, vol. 173, no 2., 15 July 2004 (2004-07-15), pages 1078-1084, 1066, XP002341373 ISSN: 0022-1767 page 1079 - page 1081; figure 2	
/MS/	6	-& DATABASE EMBL 'Online! 17 June 2004 (2004-06-17). "Homo sapiens RAET1G2 mRNA. complete cds; alternatively spliced." XP002341485 retrieved from EBI accession no. EM_PRO:AY172580 Database accession no. AY172580 -& DATABASE EMBL 'Online! 17 June 2004 (2004-06-17). "Homo sapiens RAET1G1 mRNA. complete cds; alternatively spliced." XP002341486 retrieved from EBI accession no. EM_PRO:AY172579 Database accession no. AY172579	
/MS/	7	DATABASE Geneseq 'Online! 3 June 2004 (2004-06-03), "Human RL5 related DNA, seq id 9." XP002341487 retrieved from EBI accession no. GSN: ADL23365 Database accession no. ADL23365 the whole document	
/MS/	8	Copy of The International Search Report and The Written Opinion of The International Searching Authority dated September 05, 2005.	
Examiner Signature	/Michael Szperka/		Date Considered 07/12/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number (optional). <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-0100 and select option 2